pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Bortezomib
drug
save

Bortezomib Pfizer

Marketedupdated 6mo ago
by Hospira Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval4 co-mentions · 2 sources
  • drugBORTEZOMIB2 co-mentions · 2 sources
  • drugMyezom2 co-mentions · 2 sources
  • drugBoruzu2 co-mentions · 2 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and mantle cell lymphoma and 36 investigational indications.

all catalysts(1)

approval · 1
Jan 6, 2026
approval
11mo ago
BORTEZOMIB — FDA approval
Bortezomib Pfizer
→

Trials studying Bortezomib Pfizer

  • phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myelomanot yet recruitingn=750
  • phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myelomaactive not recruitingn=494
  • phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131not yet recruitingn=300
  • phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)active not recruitingn=260
  • phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatmentsrecruitingn=317
  • phase3A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Plannedrecruitingn=1,000
  • phase2A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosisrecruitingn=60
  • phase3A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapycompletedn=395

Patent cliff

source: FDA Orange Book
first barrier falls
Nov 3, 2032
~6.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (7)

  • Sep 23, 2042method-of-use (U-3633)US 11679119
  • Sep 23, 2042method-of-use (U-3633)US 11679119
  • Sep 23, 2042method-of-use (U-3633)US 11752164
  • Sep 23, 2042method-of-use (U-3633)US 11752164
  • Sep 23, 2042formulationUS 12005069
  • Sep 23, 2042formulationUS 12005069
  • Nov 3, 2032formulationUS 8962572

News(1)

  • Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
    Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.
    onclive · 6mo ago
brand
Bortezomib
generic
bortezomib
indication
Mantle Cell Lymphoma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?